| Discuss basic science behind the human immune response |
|
|
|
|
|
| Describe how the checkpoint inhibitors alter the body’s immune response to non-small cell lung cancer cells |
|
|
|
|
|
| Describe potential toxicities associated with checkpoint inhibitors, including etiology of these toxicities and management and/or prophylaxis |
|
|
|
|
|
| Explain how checkpoint inhibitors differ from other available treatment options for metastatic NSCLC, including kinase inhibitors and cytotoxic chemotherapy |
|
|
|
|
|
| Identify FDA approved checkpoint inhibitors and their indications, including relevant aspects of patient selection |
|
|
|
|
|
